A bill to amend title XIX of the Social Security Act to exclude authorized generic drugs from calculation of the average manufacturer price for purposes of the Medicaid drug rebate program, and for other purposes.
About This Bill
Committee
Latest Action · June 11, 2019
Read twice and referred to the Committee on Finance.
Fair and Accurate Medicaid Pricing Act of 2019 or the Fair AMP Act
This bill alters certain requirements and definitions under the Medicaid Drug Rebate Program relating to rebate calculations. Specifically, the bill repeals the requirement that drug manufacturers include the prices of certain authorized generic drugs when determining the average manufacturer price (AMP) of brand-name drugs (also known as a "blended AMP"), and excludes manufacturers from the definition of "wholesalers" for purposes of rebate calculations.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.